JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De, S. K.
Right arrow Articles by Kerstein, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De, S. K.
Right arrow Articles by Kerstein, M. D.
Journal of the American Podiatric Medical Association Volume 92 Number 1 19-23 2002
Copyright © 2002 American Podiatric Medical Association

Wound Treatment with Human Skin Equivalent

Sumit K. De, BA*, Ernane D. Reis, MD{dagger} and Morris D. Kerstein, MD{ddagger}

* Submitted during second year, University of Michigan Medical School, Ann Arbor, MI.
{dagger} Assistant Professor, Department of Surgery, Mount Sinai Medical Center, New York, NY.
{ddagger} Professor and Vice Chairman, Department of Surgery, Mount Sinai Medical Center, New York, NY. Mailing address: 1214 Valley Rd, Villanova, PA 19085-2124.

Abstract

Skin grafting provides an effective means of closing chronic wounds. Autografts and allografts are used most often in skin grafting, but Apligraf, a tissue-engineered bilayered human skin equivalent, provides another safe and effective grafting option for treating diabetic, venous, and pressure ulcers. This skin equivalent has an epidermis and dermis similar to human skin, largely due to its derivation from neonatal foreskin. Apligraf is also easily accessible and has shown little immunoreactivity. (J Am Podiatr Med Assoc 92(1): 19-23, 2002)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Podiatric Medical Association.